CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 115 enrolled
Drug / intervention
Lignocaine +1 moredrug
Likely dose
Lignocaine 1.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04931433
NCT04931433Phase 4Completed
CompareCT.gov

Intravenous Lignocaine as an Analgesic Adjunct in Adolescent Idiopathic Scoliosis Surgery (IGNITE-AIS Study)

University of Malaya·interventional·Posted Jun 18, 2021·Updated Jun 7, 2024

In Brief

A Phase 4 clinical trial evaluating Lignocaine and Normal saline for Adolescent Idiopathic Scoliosis and Analgesia. Completed, enrolled 115 participants across 1 site.

Detailed Summary

This is a single-center study comparing the effect of intravenous (IV) Lignocaine given throughout posterior spinal fusion surgery on the reduction of morphine usage during postoperative period in adolescent idiopathic scoliosis (AIS) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdolescent Idiopathic Scoliosis, Analgesia
CountriesMalaysia
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 18, 2021
Enrollment StartDec 24, 2020
Primary CompletionMar 31, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.0 years ago

Interventions

Lignocainedrug

Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.

Normal salinedrug

Group B will receive saline of similar volume and rate as Group A